GLP-1 Agonists Enter the Conversation on Psoriatic Disease
GLP-1 agonists are reframing cardiometabolic risk management in psoriatic disease, giving dermatologists a direct tool against the comorbidities they see at every visit.
Topic
Glp 1 Agonists
Topic
Glp 1 Agonists
GLP-1 Agonists Enter the Conversation on Psoriatic Disease
Dermatology Times reports GLP-1 agonists are being discussed for metabolic risk in psoriatic disease; the item names no trials, d…
Medscape Asks Whether GLP-1 Therapy Is Reshaping Aesthetic Dermatology
Medscape frames 'Ozempic face' as a question rather than a verdict. The headline invites scrutiny of an emerging aesthetic concer…
Novo Nordisk CEO Targets Longevity and Aesthetics Beyond Weight Loss
Novo Nordisk's CEO has outlined a strategic pivot beyond the GLP-1 weight-loss franchise into longevity science and medical aesth…